These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26945657)

  • 21. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
    Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
    Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
    Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
    Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.
    Mengus C; Le Magnen C; Trella E; Yousef K; Bubendorf L; Provenzano M; Bachmann A; Heberer M; Spagnoli GC; Wyler S
    J Transl Med; 2011 Sep; 9():162. PubMed ID: 21943235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer.
    Yu M; Yang C; Wang S; Zeng Y; Chen Z; Feng N; Ning C; Wang L; Xue L; Zhang Z
    Clin Chim Acta; 2020 Nov; 510():437-441. PubMed ID: 32791134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia.
    Gunawan RR; Astuti I; Danarto HR
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):1095-1099. PubMed ID: 36974566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
    Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
    J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy.
    Xie GS; Lyv JX; Li G; Yan CY; Hou JQ; Pu JX; Ding X; Huang YH
    Chin Med J (Engl); 2016 Aug; 129(15):1800-4. PubMed ID: 27453228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer.
    Koike A; Robles BEF; da Silva Bonacini AG; de Alcantara CC; Reiche EMV; Dichi I; Maes M; Cecchini R; Simão ANC
    Sci Rep; 2020 Jun; 10(1):9093. PubMed ID: 32499542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors.
    Hilz H; Noldus J; Hammerer P; Buck F; Lück M; Huland H
    Eur Urol; 1999 Oct; 36(4):286-92. PubMed ID: 10473986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
    Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
    Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.